Treating stomach cancer in the belly lining with added immunotherapy
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial studies a combination treatment for stomach (or stomach-to-esophagus) cancer that has spread to the belly lining. It tests whether adding the immunotherapy drug sintilimab to a procedure called HIPEC can improve outcomes for people who have not had prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach (or gastroesophageal junction) adenocarcinoma confirmed by a lab biopsy
- You’re age 18 to 75, and if you’re able to become pregnant you are not currently pregnant
- Your performance status is good (ECOG 0–1), meaning you can do most daily activities
- Your cancer is HER-2 negative on tumor testing (IHC or FISH)
- Your cancer has spread only to the belly lining (peritoneal metastasis confirmed by a look inside with a camera), and PCI is 20 or less
- You have not had any prior systemic treatment for gastric cancer (no chemo, targeted therapy, or immunotherapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests combining standard chemotherapy and immunotherapy (tirelizumab) with heated chemotherapy given directly into the belly. It aims to treat stomach cancer that has spread to the abdominal lining, and may help shrink or control the cancer.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests a combination of an immunotherapy drug (sintilimab) and a low-dose weekly chemotherapy regimen before surgery for locally advanced stomach cancer that can be removed. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This study tests whether a thorough surgery to remove stomach cancer in the abdomen, followed by chemotherapy given through the belly and by vein, can improve outcomes. It’s for people newly diagnosed with stomach cancer that has limited spread to the belly lining.
This trial tests a combination of two drugs – a new form of irinotecan (liposomal irinotecan) and an immunotherapy drug called sintilimab – for people with stomach cancer that has progressed after initial treatment. The goal is to see if this combination can work as a second-line option.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.